Meta-Analysis of PCSK9 Inhibitors for Cardiovascular Risk in Peripheral Artery Disease

A systematic review and meta-analysis of 6 studies involving 4,563 patients with peripheral artery disease, authored by Dwi Ariyanti and published on figshare in April 2026. The work evaluates the effects of PCSK9 inhibitors on cardiovascular, functional, limb, and survival outcomes compared to placebo or standard therapy.

Use Cases

• Training meta-analysis models based on aggregated clinical trial results.
• Studying treatment effect heterogeneity for cardiovascular drugs in a specific patient population.
• Validating statistical methods for synthesizing data from randomized controlled trials and cohort studies.

Strengths

• Includes data from 6 studies (5 RCTs, 1 cohort) with 4,563 total patients.
• Reports specific quantitative results, including hazard ratios and confidence intervals for outcomes like MACE.
• Provides a clear methodological description of systematic search and analysis models.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 725.1 KB document, indicating a limited scope focused on the review's results rather than raw patient-level data.

Provenance

Source

figshare, authored by Dwi Ariyanti.

Collection Method

Systematic search of PubMed, Scopus, and ClinicalTrials.gov through August 2025, with data analyzed using fixed- or random-effects models.

Time Range

Studies included through August 2025.

Freshness

Last updated 2026-04-30 07:55:29; freshness should be verified.

Geography

Global (studies sourced from international databases).